By: Tim Tedeschi, University of Cincinnati From: medicalxpress.com While better screening and improved treatments are leading to better outcomes for patients with breast cancer, 90% of breast cancer deaths are a result of metastasis, or the cancer growing and spreading to other parts of the body. University of Cincinnati Cancer Center researchers in the lab of Jun-Lin Guan, Ph.D., have …
This revolutionary breast cancer drug has saved millions of lives in its 25-year history
By: Dennis J. Slamon, MD (FEL ’82), PhD From: uclahealth.org In the early 1990s, women who were diagnosed with the HER2-positive subtype of breast cancer weren’t expected to live more than three-to-five years after diagnosis. Now, depending on the stage of the cancer at diagnosis, women with HER2-positive breast cancer have among the highest survival rates of all women with …
Trastuzumab Deruxtecan Elicits Superior HRQOL in HER2+ Metastatic Breast Cancer
By: Caroline Seymour From: onclive.com Patient-reported outcomes, including time to definitive deterioration of global health status and overall quality of life (QOL) with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic breast cancer reflected the regimen’s favorable risk-benefit profile in the phase 3 DESTINY-Breast02 trial (NCT03523585), according to findings presented during the 2023 ESMO Breast Cancer Annual Congress. Global health status and …
Progress in Treating Brain Metastases in Breast Cancer Puts Multidisciplinary Approaches Into Focus
By: Chris Ryan From: onclive.com Brain metastases are a common complication in patients with breast cancer, and although systemic therapies for patients with HER2-positive disease have displayed promise in penetration of the blood-brain barrier, work remains for subsets of patients with central nervous system (CNS) metastases, according to Barbara O’Brien, MD.1 “For most patients, the treatment [for brain metastases has …
Next Steps Following DESTINY-Breast03 for HER2+ Breast Cancer
By: Erika P. Hamilton, MD From: targetedonc.com Another area that needs to be investigated is the sequencing of current agents once trastuzumab deruxtecan is used in the second line. Other agents used in HER2-positive disease including capecitabine (Xeloda), tucatinib (Tukysa), and trastuzumab (Herceptin) will need to be investigated in terms of their efficacy following the newer agent and what the …
Presence of Tumor-Infiltrating Lymphocytes Following Neoadjuvant Treatment May Contribute to Worse Survival in Patients With HER2-Positive Breast Cancer
From: ascopost.com Patients with HER2-positive breast cancer may be less likely to survive if their initial treatment fails to eradicate the tumor completely and they have high levels of tumor-infiltrating lymphocytes in their residual tumors, according to a new study published by Miglietta et al in the European Journal of Cancer. The findings were also presented at the 13th European …
Team identifies how certain immune cells contribute to worse survival rates in HER2-positive breast cancer patients
From: medicalxpress.com Patients with a type of breast cancer called HER2-positive are less likely to survive if their initial treatment fails to eradicate the tumor completely and they have high levels of immune cells called tumor infiltrating lymphocytes in the residual disease. Dr. Federica Miglietta told the 13th European Breast Cancer Conference that normally tumor infiltrating lymphocytes (TILs) help the …
Overview of Trastuzumab Biosimilars in HER2-positive Breast Cancer
By: Skylar Jeremias From: centerforbiosimilars.com Authors of a systematic review summarized the results of 21 published studies on the efficacy, safety, and cost-benefit ratio of trastuzumab biosimilars in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The HER2 Receptor and Trastuzumab Use in HER2-positive Breast Cancer HER2 is a cell surface receptor activated by epidermal growth factor that upon …
Neoadjuvant and Adjuvant Therapy Elicit Similar Efficacy in Early-Stage HER2+ Breast Cancer
By: Chris Ryan From: onclive.com Neoadjuvant therapy generated similar benefits to adjuvant therapy in patients with early-stage, HER2-positive breast cancer treated in China, suggesting that neoadjuvant therapy should be used in this patient population, according to data from a real-world retrospective study published in The Breast.1 At a median follow-up of 54.1 months (interquartile range, 40.8-68.9), all patients treated with …
FDA expands Enhertu approval for breast cancer
From: healio.com The FDA expanded the approval of fam-trastuzumab deruxtecan to include treatment of patients with HER2-positive metastatic breast cancer who received a prior anti-HER2-based regimen. Fam-trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a novel antibody-drug conjugate with three components: a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino acid sequence as trastuzumab (Herceptin, Genentech); a topoisomerase 1 …